Barclays
DRUG icon

Barclays’s Bright Minds Biosciences DRUG Stock Holding History

Barclays’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$146K Sell
2,940
-316
-10% -$22.3K ﹤0.01% 4148
2026
Q2 		$229K Buy
3,256
+179
+6% +$14.1K ﹤0.01% 3623
2026
Q1 		$225K Sell
3,077
-6,583
-68% -$530K ﹤0.01% 3617
2025
Q4 		$754K Buy
9,660
+3,079
+47% +$206K ﹤0.01% 3621
2025
Q3 		$399K Sell
6,581
-1,812
-22% -$70.3K ﹤0.01% 3943
2025
Q2 		$219K Buy
+8,393
New +$252K ﹤0.01% 4215

Other funds holding DRUG

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
AdvisorShares Investments
AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Barclays's DRUG Position: Q3 2026 in Review

Barclays reduced its Bright Minds Biosciences (DRUG) stake by 9.7% in Q3 2026, selling an estimated $22.3K and leaving 2,940 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #4148.

Barclays first reported a position in DRUG in Q2 2025 and has held it in 6 quarters since. The position peaked at $754K in Q4 2025. 35 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

  • Barclays held 2,940 shares of Bright Minds Biosciences worth $146K as of Q3 2026.
  • Barclays sold 316 Bright Minds Biosciences shares in Q3 2026, an estimated $22.3K.
  • Bright Minds Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4148 holding.
  • Barclays first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 6 quarters since.
  • Barclays's Bright Minds Biosciences position peaked at $754K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.